Ensysce Biosciences, Inc.

Leisure Acquisition Corp. (LACQ), a blank-check company that completed its IPO in 2019 with a focus on the leisure and entertainment sector, announced a business combination with Ensysce Biosciences, Inc. on January 31, 2021. The deal pivoted the vehicle into the pharmaceutical biotechnology sector, as Ensysce was developing abuse-deterrent opioid and stimulant formulations using its proprietary drug-protection platform. The transaction closed, and the combined company proceeded under the Ensysce Biosciences name. LACQ's status is recorded as closed. Investors and researchers tracking SPAC deal histories, de-SPAC outcomes, and pharmaceutical sector transactions can access the full data profile for LACQ on SpacDesk — sign up at SpacDesk.com for complete coverage.

SPAC Counterparty (1)